306-N16B
目录号 : KM35299 CAS No. : 2803699-70-7 纯度 : 98%
306-N16B 是一种选择性肺部靶向脂质纳米颗粒,通过尾结构差异介导的蛋白冠选择性吸附 (如纤维蛋白原 β/γ 链),可逆性靶向肺部内皮细胞及特定免疫细胞。306-N16B 与血液中特定血浆蛋白结合形成蛋白冠,引导颗粒富集于肺部,释放 mRNA 并促进靶细胞基因表达,发挥高效肺部细胞转染活性,可精准调控肺内不同细胞类型 (如内皮细胞、巨噬细胞) 的基因递送。306-N16B 可用于包括肺淋巴管肌瘤病 (LAM) 等遗传性肺部疾病的基因疗法技术,通过递送 Tsc2 mRNA 恢复肿瘤抑制因子功能,同时可用于肺部特异性 mRNA 疫苗及基因编辑疗法。
规格 价格 是否有货 数量
1mg
In-stock
5mg
In-stock
10mg
In-stock
50mg 询价 In-stock
100mg 询价 In-stock
KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies.
分子式
C75H151N7O4S8
分子量
1471.57
CAS号
2803699-70-7
中文名称
306-N16B
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度 mg/ml;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。